Reverse Mergers and SPACs: Are APOs the New Norm for Biotechs Going Public?
The Seven Habits of Highly Effective Data Rooms
Valuation of Your Early Drug Candidate
Preparing Your Company for the M&A Process
The Art & Science of High M&A Valuation
Best Practices for Fundraising and M&A Due Diligence
This whitepaper explores the importance of establishing early goals and objectives for the process, how to get the right people to ask the right questions in advance of the process, how to build credibility by defining goals and demonstrating they can be achieved, and much more.
Must-Know Finance Concepts for Life Sciences Valuations - Part II
This whitepaper discusses which asset valuation methodology is most used by big pharma to evaluate possible partners or acquisitions and an explanation of three fundamental concepts in valuation: risk-adjusted value, cost of capital, and present value.
Demystifying Tech M&A Valuation
Must-Know Finance Concepts for Life Sciences Valuations
Earnouts: Structures for Breaking Negotiation Deadlocks
This white paper features Senior M&A Executive Javier Enrile of Principal Global Investors. Mr. Enrile provides his extensive expertise to explain how earnout, (also "earn-out") structures work and how it can reduce risk for the buyer, add attractive incentives for the seller, and serve to break negotiation deadlocks and get deals consummated.
Pivot to Cash: Bankruptcy & Restructuring in a Distressed Environment